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EVIDENCE BASED NEURO-ONCOLOGY
Management of paediatric intracranial ependymoma
Syeda Kubra Kishwar Jafri, Saqib Kamran Bakhshi, Muhammad Shahzad Shamim

Abstract
Intracranial ependymoma are relatively common paediatric
brain tumours, but their eloquent location and high
recurrence rate pose a significant challenge. Gross total
resection or maximum safe resection followed by adjuvant
radiotherapy are currently the standard recommended
treatment, although there is still nearly 50% recurrence risk
at 5 years. Chemotherapy has shown some promising
results after recent advances in molecular understanding of
ependymomas, but needs further evaluation before it could
be added to the treatment regime.
Keywords: Intracranial Ependymoma, Pediatric, Surgical
Management.

Introduction
Ependymoma are neuroepithelial tumours, and comprise 810% of all paediatric tumours.1 They are predominantly
located in the brain in the posterior fossa (70% of the cases),
but can be found in the supratentorial region and the spinal
cord.2 Intracranial ependymoma are commonly present in
the ventricles, but they can also occur in the cerebral cortex

Figure-1: (a,b) MR T1 axial plain and contrast images of a 6 year old boy with a large
heterogeneously enhancing ependymoma in the fourth ventricle, extending in to the
cerebellopontine angle and brainstem.

in the vicinity of the ependymal lining of the ventricles, and
rarely can be purely cortical with no connection to the
ventricular wall (Figure-1).3,4 The WHO classification system
classifies ependymomas into 3 grades. Grade I are benign
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(myxopapillary), grade II tumours are also benign and can
be divided into 4 sub-types (cellular, papillary, clear-cell and
tanycytic), and grade III are malignant tumours (anaplastic).
Historically, age at diagnosis, extent of surgical resection
and pathological subtypes were considered important
prognostic factors. However, there are incongruities in
literature regarding relative importance of these clinical
parameters. We have reviewed the literature to assess the
current recommendations on the management of
intracranial ependymomas, and to draw conclusions with
regards to the outcomes.

Review of Evidence
Several factors influence the most appropriate management
and outcomes of children with intracranial ependymomas.
Surgical resection has been the mainstay of treatment with
multiple objectives including tissue diagnosis, removing the
mass effect from important neural structures and to open
the CSF pathways for relieving hydrocephalus. However,
complete excision poses a challenge considering eloquent
location of these tumours. Consequently, gross total
resection (GTR) is possible in only up to 50% of the cases.5
Perilongo et al., had reviewed 92 children with
ependymomas for extent of resection, and had reported
better overall survival after GTR (69.8%) as compared to
subtotal resection (STR) (32.5%).6 They had also reported that
GTR group had a better impact on progression free survival
(57% vs 11%).6 Similar conclusions were drawn by Horn et al.,
in a series of 83 patients.7 They reported that failure to
achieve GTR, histological grade III tumours and less than 3
years age at diagnosis were all factors that resulted in
adverse outcomes in childhood intracranial ependymomas.7
Cage et al., published a systematic review on outcomes in
childhood intracranial ependymomas after combining extent
of resection and histological grade.8 Patients with grade II
ependymomas had better survival after GTR alone than with
any other treatment modality. In patients with grade III
ependymomas, STR with adjuvant radiation was associated
with better outcomes than GTR. This was attributed to the
fact that grade III tumours were more infiltrative with poorer
anatomical boundaries, and thus, aggressive resection to
achieve GTR caused more morbidity and resulted in poorer
neurological outcomes, as compared to STR.8
In a large multi-center retrospective analysis of 463 patients,
Amanda et al., reviewed children with grade II and III
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intracranial ependymomas with long clinical and radiological
follow-ups.9 Extent of resection, tumour sub-type and type of
treatment were significantly associated with better overall
survival in their study. GTR was superior to STR for 5-year
survival (75 ± 5% vs. 54 ± 8%; p = 0.002).9 However, there was
high recurrence rate within 10 years of diagnosis which
brought overall survival to 61 ± 7% at 10 years; so GTR was not
curative for all children.9 They proposed that GTR alone is not
sufficient to treat children with intracranial ependymomas
and recommended adjuvant treatments after surgery for
better outcomes.9 Some studies have also proposed 'secondlook' surgery for residual ependymomas, however, a large
cohort published by Italian investigators found no long-term
significant difference in outcomes of children who
underwent single surgery with adjuvant therapy, and those
who underwent 'second-look' surgery.10
Although radiation alone does not have a significant role in
treatment of ependymomas, it has been shown to improve
survival when coupled with surgical resection, particularly in
cases where GTR is not possible, as shown in the study by
Cage et al.8 Adjuvant radiotherapy is now part of the
standard treatment protocol at most centers for children
more than 3 years of age.11 Historically, prophylactic
radiation was also administered to the whole neural axis to
prevent recurrence. However, it has not proven to be of any
benefit in preventing recurrence and distal metastasis. The St
Jude RT-1 trial had recruited 88 children with ependymomas
who were administered radiation and followed up for a
median of 38.2 months. They concluded that limited volume
local irradiation results in good disease control (3-year
progression-free survival estimate was 74.7% 5.7%).12

Conclusion
Extent of resection is the prime prognostic factor followed by
age at presentation, both of which have a direct relation to
the favourability of outcomes. GTR followed by adjuvant focal
radiation remains the optimal choice for paediatric cranial
ependymomas and has significantly improved the overall
survival and progression-free survival over 5 years follow ups.
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